{"filing":{"accession_number":"0001372514-26-000059","cik":"0001372514","ticker":"KPHMW","company_name":"KIORA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"kprx-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/kprx-20260610.htm"},"events":[{"id":5716,"run_id":5008,"accession_number":"0001372514-26-000059","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Kiora Pharmaceuticals held its Annual Meeting on June 10, 2026, with shareholders voting on four proposals: election of three Class II Directors (Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.), a non-binding advisory vote on named executive officer compensation, ratification of Haskell \u0026 White LLP as independent auditor, and approval of a 1,500,000 share increase to the 2024 Equity Incentive Plan. All four proposals passed.","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":6027,"accession_number":"0001372514-26-000059","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2024 Equity Incentive Plan increasing available shares by 1,500,000 shares. This is a compensatory arrangement amendment requiring shareholder approval under Item 5.02(e), affecting the pool of equity available for executive and employee compensation. The material increase in authorized shares under the equity plan is directly relevant to investor assessment of dilution and compensation practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T10:02:15.933262+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6028,"accession_number":"0001372514-26-000059","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of the Annual Meeting held on June 10, 2026. The filing presents voting outcomes for four proposals: election of three Class II Directors (Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.), non-binding advisory vote on named executive officer compensation, ratification of Haskell \u0026 White LLP as independent auditor, and approval of a 1,500,000 share increase to the 2024 Equity Incentive Plan. All proposals passed. Shareholder vote results are material to investors as they reflect governance decisions and capital allocation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T10:02:15.933262+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6027,"accession_number":"0001372514-26-000059","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2024 Equity Incentive Plan increasing available shares by 1,500,000 shares. This is a compensatory arrangement amendment requiring shareholder approval under Item 5.02(e), affecting the pool of equity available for executive and employee compensation. The material increase in authorized shares under the equity plan is directly relevant to investor assessment of dilution and compensation practices.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T10:02:15.933262+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-06-10"},{"id":6028,"accession_number":"0001372514-26-000059","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of the Annual Meeting held on June 10, 2026. The filing presents voting outcomes for four proposals: election of three Class II Directors (Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.), non-binding advisory vote on named executive officer compensation, ratification of Haskell \u0026 White LLP as independent auditor, and approval of a 1,500,000 share increase to the 2024 Equity Incentive Plan. All proposals passed. Shareholder vote results are material to investors as they reflect governance decisions and capital allocation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T10:02:15.933262+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-06-10"}]}